Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells $83,606.25 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 4,375 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25. Following the completion of the transaction, the insider owned 180,040 shares of the company’s stock, valued at $3,440,564.40. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Price Performance

Shares of BBNX opened at $19.42 on Friday. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71. The company has a 50-day simple moving average of $17.17 and a two-hundred day simple moving average of $13.65. The firm has a market capitalization of $873.71 million, a PE ratio of -11.77 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. Analysts expect that Beta Bionics, Inc. will post -2.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BBNX shares. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Truist Financial increased their price target on shares of Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. UBS Group assumed coverage on shares of Beta Bionics in a research note on Tuesday, July 28th. They set a “buy” rating and a $22.00 price objective on the stock. The Goldman Sachs Group upped their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, William Blair assumed coverage on shares of Beta Bionics in a research note on Friday, August 21st. They set a “market perform” rating for the company. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus price target of $20.10.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Institutional Investors Weigh In On Beta Bionics

A number of institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System raised its position in shares of Beta Bionics by 306.1% in the 2nd quarter. California State Teachers Retirement System now owns 8,556 shares of the company’s stock worth $134,000 after purchasing an additional 6,449 shares during the last quarter. Bank of America Corp DE bought a new position in Beta Bionics in the 2nd quarter worth about $8,566,000. Man Group plc purchased a new stake in Beta Bionics during the 2nd quarter valued at about $419,000. Legal & General Group Plc purchased a new stake in Beta Bionics during the 2nd quarter valued at about $62,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Beta Bionics during the 2nd quarter valued at about $172,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.